SAB Biotherapeutics (SABS) Gains from Sales and Divestitures (2023 - 2026)
SAB Biotherapeutics (SABS) reported Gains from Sales and Divestitures of $4180.0 for Q1 2026, little changed on a YoY basis from $4183.0 in Q1 2025, and down 75.0% quarter-over-quarter from $16723.0 in Q4 2025.
SAB Biotherapeutics (SABS) Gains from Sales and Divestitures (2023 - 2026) Analysis & Trends
SAB Biotherapeutics has reported Gains from Sales and Divestitures for 4 years, with the latest figure at $4180.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Sales and Divestitures changed 0.07% year-over-year to $4180.0; the trailing twelve-month figure through Mar 2026 stood at $4180.0 (changed 0.07% YoY), and the FY2025 full-year result was $16723.0, down 26.36% from the prior year.
- Gains from Sales and Divestitures for Q1 2026 stood at $4180.0, down from $16723.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $106250.0 in Q3 2023, with the low at $4180.0 in Q1 2026.
- Historically, Gains from Sales and Divestitures has averaged $25704.7 across 4 years, with a median of $14769.5 in 2023.
- Annual changes were most pronounced in 2024 — Gains from Sales and Divestitures plunged 94.42% — and 2025, when it surged 100.0%.
- SAB Biotherapeutics' Gains from Sales and Divestitures stood at $12816.0 in 2023, then surged by 77.19% to $22709.0 in 2024, then decreased by 26.36% to $16723.0 in 2025, then sank by 75.0% to $4180.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $4180.0 (Q1 2026), $16723.0 (Q4 2025), and $12544.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | SAB Biotherapeutics | 214.77 Mn | 214.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,180.00 |
| Mar 31, 2026 | 4,180.00 |
| Dec 31, 2025 | 16,723.00 |
| Dec 31, 2025 | 16,723.00 |
| Sep 30, 2025 | 12,544.00 |
| Sep 30, 2025 | 12,544.00 |
| Jun 30, 2025 | 8,364.00 |
| Jun 30, 2025 | 8,364.00 |
| Mar 31, 2025 | 4,183.00 |
| Mar 31, 2025 | 4,183.00 |
| Dec 31, 2024 | 22,709.00 |
| Dec 31, 2024 | 22,709.00 |
| Sep 30, 2024 | 18,527.00 |
| Sep 30, 2024 | 18,527.00 |
| Jun 30, 2024 | 4,182.00 |
| Jun 30, 2024 | 4,182.00 |
| Mar 31, 2024 | 22,978.00 |
| Mar 31, 2024 | 22,978.00 |
| Dec 31, 2023 | 12,816.00 |
| Dec 31, 2023 | 12,816.00 |